dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Voss, Martin H. |
dc.contributor.author | Gordon, Michael S. |
dc.contributor.author | Mita, Monica |
dc.contributor.author | Rini, Brian |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Makker, Vicky |
dc.date.accessioned | 2021-11-05T06:58:39Z |
dc.date.available | 2021-11-05T06:58:39Z |
dc.date.issued | 2020-11 |
dc.identifier.citation | Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 Nov;123:1590–8. |
dc.identifier.issn | 1532-1827 |
dc.identifier.uri | https://hdl.handle.net/11351/6503 |
dc.description | Teràpia del càncer; Càncer ginecològic; Càncer urològic |
dc.description.sponsorship | This study was supported by Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. NIH/NCI Cancer Center Support Grant (Memorial Sloan Kettering Cancer Center, P30 CA008748). |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | British Journal of Cancer;123 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Medicaments - Administració |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Maximum Tolerated Dose |
dc.title | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41416-020-01041-x |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | dosis máxima tolerada |
dc.relation.publishversion | https://doi.org/10.1038/s41416-020-01041-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Voss MH, Makker V] Department of Medicine, 300 East 66th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. [Gordon MS] Oncology Research, HonorHealth Research Institute, 10510 N 92nd St Suite 200, Scottsdale, AZ 85258, USA. [Mita M] Department of Hematology and Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd North Tower, Los Angeles, CA 90048, USA. [Rini B] Cleveland Clinic Foundation, Department of Solid Tumor Oncology, 9500 Euclid Avenue, Cleveland, OH 44195, USA. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32913286 |
dc.identifier.wos | 000568843200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |